secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2026-06-22T20:05:14+00:00
Accession:  0001193125-26-277511
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ORIC shareholders approve amended equity plan, elect two Class III directors at annual meeting
--------------------------------------------------------------------------------

- Shareholders approved amended 2020 Equity Incentive Plan (61.2M for, 27.3M against); annual share increase cut from 5% to 4% of outstanding, evergreen cap removed.
- Jacob Chacko, M.D. and Mardi C. Dier elected as Class III directors; Chacko received 89.3M for, Dier 82.0M for.
- KPMG ratified as independent auditor for FY2026 with 94.5M votes in favor; advisory say-on-pay passed with 88.5M for.
- Advisory vote favored annual frequency of future say-on-pay votes (89.4M for one year); next frequency vote by 2032.
- Turnout of 91.4% of outstanding shares; plan amendment saw 27.3M against, reflecting notable shareholder dissent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000119312526277511/0001193125-26-277511-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000119312526277511/d103876d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-277511

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer